- Dec 30, 2015
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)
STORM Selinexor Treatment of Refractory Myeloma (STORM) This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg...
221
- Dec 18, 2015
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab...
181
- Dec 18, 2015
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
STOMP Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP) This study will independently assess the efficacy and safety...
409
- Dec 10, 2015
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma A Phase 1 Study in Subjects With Relapsed or...
158
- Dec 10, 2015
NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas,...
173
- Dec 9, 2015
NCT02519452: Phase 1 - Daratumumab + Recombinant Human Hyaluronidase (rHuPH20) RRMM - PAVO Study
MMY1004 (PAVO) Study RRMM The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and...
288